The selective endothelin-a receptor antagonist improves quality of life (QOL) weighted time to progression in hormone refractory prostate cancer patients
- 30 April 2001
- journal article
- abstracts
- Published by Elsevier in European Journal Of Cancer
- Vol. 37, S220
- https://doi.org/10.1016/s0959-8049(01)81300-9
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: